H eart failure (HF) is a major and growing public health problem in the United States that accounts for >1 million hospital admissions per year and affects close to 6 million Americans. 1 Of patients with incident HF in epidemiological studies, 40% to 71% have HF with preserved, rather than reduced, ejection fraction (HFpEF versus HFrEF), and HFpEF is more common in women. [1] [2] [3] [4] [5] [6] [7] HFpEF is increasing in prevalence 1 and as opposed to HFrEF, limited effective therapy are presently available. To guide future therapeutic considerations, there is a need to better understand the risk factors and natural history of HFpEF.
Risk Factors for Incident Heart Failure
in multiethnic cohorts but without ejection fraction data or have studied survival of those with prevalent HFpEF. [8] [9] [10] [11] As such, there is an important need to evaluate risk factors for incident HFpEF and HFrEF, especially in women who are understudied.
The Women's Health Initiative recently readjudicated HF in a subcohort of women that differentiates acute from chronic HF and allows for the evaluation of incident hospitalized HFpEF and HFrEF. 12, 13 We therefore sought to identify risk factors for HFpEF and HFrEF in women in this subcohort and to better understand the role of race/ethnicity in explaining any differences in HFpEF and its risk factors. For those HFpEF and HFrEF risk factors that were amenable to prevention, we assessed their population-attributable risk percentage (PAR%) to estimate the amount of HFpEF and HFrEF that could be theoretically reduced if these risk factors were eliminated.
Methods

Study Population
The Women's Health Initiative recruited women nationwide in 40 clinical centers between 1993 and 1998. Details of the recruitment, baseline questionnaires, and examinations performed have been published previously. [14] [15] [16] Briefly, study participants were women 50 to 79 years of age at baseline who had no terminal illness and were eligible for either the clinical trials or observational arm, completed baseline assessments, including several self-administered questionnaires of sociodemographic characteristics, medical history, reproductive and menstrual history, health behavior, and family history of selected diseases. Of the 161 808 postmenopausal women in the original cohort, a subcohort of 44 174 women were evaluated for hospitalized HF from baseline through January 13, 2015. To allow for evaluation of racial and ethnic differences with adequate statistical power, we excluded those whose self-reported race was Asian/Pacific islander, Native American, or unknown race/ethnicity (n=1042). To evaluate a disease-free cohort, we excluded 505 women with self-reported HF at baseline and 444 who had chronic HF on their first adjudication. The final analytic cohort was 42 170 women. This study received institutional review board approval, and all participants signed informed consents at all 40 clinical centers.
Outcomes
Hospitalized HF was adjudicated based on self-report of a hospitalization related to HF or coronary heart disease (CHD) by trained adjudicators. 12, 13 Details of the adjudication process for acute HF are given in Appendix I in the Data Supplement. Acute HF with an ejection fraction <45% was considered HFrEF. Acute HF with an ejection fraction ≥45% was considered HFpEF. If no ejection fraction was available, it was classified as heart failure with unconfirmed ejection fraction. We performed an additional sensitivity analysis defining HFpEF as an ejection fraction of ≥50% and HFrEF as <50%.
The acute HF classification system used in this analysis has been shown to have good agreement with other HF epidemiological algorithms including Framingham (69.5%), modified Boston (63.7%), National Health and Nutrition Examination Survey (60.9%), Gothenburg (59.5%), and the International Classification of Diseases, Ninth Revision, Clinical Modification (62.9%) and demonstrates modest kappa coefficients (0.32-0.10). 12
Clinical Covariates
Race/ethnicity was self-reported as African American, Hispanic/ Latino, white (not of Hispanic origin), or other. 14, 15 Clinical covariates include age, education, income, cigarette smoking, current hormone use, hypertension, diabetes mellitus, atrial fibrillation, CHD, chronic lung disease, physical activity, medication use, alcohol use, comorbid conditions, and anemia. Details can be found in Appendix II in the Data Supplement.
Statistical Methods
Baseline characteristics are reported separately by race/ethnicity and because of differences in age in the race/ethnicity groups, percentages are adjusted to the 5-year age distribution of the hormone therapy participants. Annualized event rates were also age adjusted as above, with 95% confidence intervals computed using a bootstrap method with 5000 repetitions.
Primary analyses used time-to-event methods based on the Cox regression model. Time is defined as days from randomization in the hormone therapy or from Women's Health Initiative enrollment for non-hormone therapy participants to the event or censoring. Censoring is the earliest of HF of a different type, death, end of follow-up, or January 13, 2015. All models were stratified by study component (clinical trial or observational study) and age strata used for clinical trial randomization. Cox regression models use the Wald χ 2 test to evaluate the effect of each individual variable while simultaneously adjusting for all variables in the model. Tests for interactions are based on likelihood ratio tests. PAR% were calculated using the standard definitions. 17
Results
Of the subcohort of 42 170 women evaluated for incident hospitalized HF, 51.2% were white, 33.6% were African American, and 15.2% were Hispanic. At baseline, African American and Hispanic women were younger than white women; therefore, age-adjusted baseline comparisons have been made ( Table 1 ). African American women had lower incomes, were more likely to be obese, less physically active, and had higher prevalence of hypertension, diabetes mellitus, CHD, myocardial infarction (MI), stroke than their white counterparts. In addition, African American women were more likely to have had a hysterectomy, have anemia, and less likely to be on aspirin. Hispanic women were less educated, had lower incomes, had less health insurance, more likely to have diabetes mellitus, and have had a hysterectomy and were less likely to be current smokers and to take aspirin than white women.
Of the 42 170 women, followed up for a mean of 13.2 years, there were 1952 cases of acute incident hospitalized HF. Of these 1952 cases, 70.7% had troponin measures, 38.9% had brain naturietic protein, and 6.1% had N terminal pro brain naturietic protein assessed. Ejection fraction was determined at the time of HF hospitalization in 1419 cases (73%). Of these, 85% were determined by transthoracic echocardiogram, 1% by radionuclideventriculogram, 11% by angiography, 1% by stress echo, and 2% by transesophageal echocardiogram.
Of the 1952 cases of acute incident hospitalized HF, 902 (46.2%) met the definition of HFpEF, 508 (26.0%) were HFrEF, 533 (27.3%) were of unknown ejection fraction, and 9 cases initially had a reduced ejection fraction that improved to normal. Annualized incidence rates were 0.35% for incident hospitalized HF, 0.16% for HFpEF, and 0.09% for HFrEF with higher incident rates for HFpEF, compared with HFrEF for all race/ethnicity groups. White women were more likely to develop both HFpEF and HFrEF compared with African American and Hispanic women, with age-adjusted annualized incidence (%) and 95% confidence interval (CI) of 0.20 
Risk Factors for HFpEF Compared With HFrEF
We examined risk factors for hospitalized incident HFpEF and HFrEF ( 
Differences in HFpEF Between African American, Hispanic American, and White Women
We evaluated risk factors for incident hospitalized HFpEF and HFrEF stratified by race/ethnicity ( CHD indicates coronary heart disease; Hgb, hemoglobin; MI, myocardial infarction; and NMSC, non-melanoma skin cancer. *Percentages are age adjusted to the 5-y age distribution of the hormone trial participants. †CHD includes MI, CABG/PCI, and angina requiring medication. ‡Current use is randomization arm for the hormone therapy trial participants or current E-alone use reported at baseline for non-hormone therapy participants with a hysterectomy or current E+P use reported at baseline for non-hormone therapy participants without a hysterectomy. §Mean (SD) are age adjusted to the 5-y age distribution of the Hormone Trial participants. 
Population-Attributable Risk% for HFpEF and HFrEF
To assess the impact of potential preventive strategies for HFpEF and HFrEF, the PAR% for risk factors that are amenable to change and prevalent in the population (hypertension, obesity, diabetes mellitus, and CHD) were calculated (Figure) . For HFpEF, approximately two thirds of the PAR% is associated with hypertension and obesity, whereas diabetes mellitus and CHD make up approximately one fourth of the PAR%. For African American women, hypertension and obesity were associated with >90% of the PAR%, and for Hispanic women, the same risk factors were associated with ≈72% of the PAR%. For HFrEF, hypertension showed the strongest PAR% in all 3 race/ethnicity groups.
Discussion
This study of incident hospitalized HFpEF and HFrEF in a multiethnic cohort of women confirms previous findings that HFpEF is of greater incidence than HFrEF in postmenopausal women and that risk factors for both HFpEF and HFrEF include age, CHD, diabetes mellitus, smoking, and hypertension. Robust associations for HFpEF, but not HFrEF, include obesity, number of comorbid conditions, anemia, and atrial For risk factors with >2 levels, the statistical significance applies to the inclusion of the entire term in the model. NA indicates insufficient number of cases to estimate HR. BMI indicates body mass index; BP, blood pressure; CABG, coronary artery bypass graft; CHD, coronary heart disease (MI, CABG, PCI, or angina requiring medication); CI, confidence interval; DM, diabetes mellitus (treated with pills or shots); HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazards rate; Hx, history; MI, myocardial infarction; PCI, percutaneous coronary intervention; and HT, hormone therapy.
*All HR and 95% CI are estimated from multivariable Cox proportional hazard models stratified by study component (clinical trial or observational study) and age strata (50-54, 55-59, 60-69, 70-79) and adjusted for all listed risk factors simultaneously.
†P<0.0001. ‡P<0.001. §P<0.01. ‖P<0.05. fibrillation. As expected, MI is a risk factor for HFrEF. This study is unique in describing the importance of obesity as a risk factor for HFpEF and its PAR%, with special significance for African American women. Although the important role of hypertension as a risk factor for both HFpEF and HFrEF is well documented, the important role of obesity as a risk factor in women for HFpEF is less well known. Ho et al 17 found a similar result for obesity as a risk factor for incident HFpEF in both sexes in the Framingham Heart study, as did Gupta et al 11 in the Atherosclerosis Risk in Communities study for prevalent HFpEF in African Americans. Lam et al found stronger association of obesity in women compared with that in men in the baseline assessment of participants in the I-PRESERVE trial. 18 Brouwers et al 19 in the Dutch Prevend study found obesity to be a risk factor for both HFpEF and HFrEF. The pathophysiologic mechanisms by which higher BMI levels are associated with higher rates of incident HFpEF may well be related to adverse effects on obesity on skeletal muscle, oxidative stress, inflammation, and insulin resistance, all contributors Figure. A, Population-attributable risk (PAR)* by race and ethnicity for heart failure with preserved ejection fraction. *Sum of PAR% within race/ethnicity may be >100% as incidence rates are not adjusted for other risk factors. B, PAR* by race and ethnicity for heart failure with reduced ejection fraction. *Sum of PAR% within race/ethnicity may be >100% as incidence rates are not adjusted for other risk factors. Risk Factors for Incident Heart Failure to HFpEF. 20 Recently, Paulus and Tschöpe 21 have proposed that obesity through the above mechanisms may induce changes in the coronary microvascular endothelium, whereas Mohammed et al 22 has shown associations with coronary microvascular rarefaction with HFpEF as another potential mechanism.
Although overweight and obesity are risk factors for incident HF and for HFpEF in most studies, both Haass et al 23 and Kao et al 24 have demonstrated in the I-PRESERVE and CHARM preserved trials that HFpEF participants with either lower BMIs and higher BMIs predicted more cardiovascular events and decreased survival. This apparent paradox might be explained by cardiac cachexia and nutritional deficiencies associated with lower BMI, 25 whereas a BMI >35 kg/m 2 is associated with higher rates of glucose intolerance, metabolic syndrome, and chronic inflammation, all of which contribute to worse cardiovascular outcomes and higher levels of mortality. 20 The importance of overweight and obesity in the potential prevention of HFpEF in women, especially in African American women, is noteworthy given its high PAR%. Why overweight and obesity places African American women at higher risk for HFpEF compared with white women even when adjusting for diabetes mellitus and hypertension is unknown, but differences in inflammatory obesity, insulin sensitivity, and visceral fat distribution might play a role in these findings. The potential synergy between weight loss and exercise in obese, sedentary women and their impact on the prevention of HFpEF are worthy of future trials. Indeed, in those with HFpEF, a recent trial showed an improvement in peak oxygen consumption with additive effects for weight loss and exercise. 26 Our study is the largest study in postmenopausal women to evaluate clinical risk factors for incident hospitalized HF with preserved and reduced ejection fractions and allows for race/ethnicity comparisons. An additional strength of our study was that it used a well-validated classification system in defining new-onset incident hospitalized HF and its subtypes.
Our study has several important caveats to consider when evaluating its conclusions. First, it relied on hospitalized HF, and therefore, outpatient-diagnosed HF was not captured. However, outpatient-diagnosed HF is <25% of HF, is equally distributed between HFpEF and HFrEF, and leads to subsequent hospitalization within a relatively short period of time. 27 In addition, ejection fraction information while captured in the majority of HF outcomes was missing in 27%, leading to potential misclassification bias. We may have overestimated the frequency of HFrEF by using an ejection fraction of <45% compared with a more stringent ejection fraction of <40% to categorize as many participants as either HFpEF or HFrEF in our cohort. In addition, the differential association between some risk factors and type of HF could be because of dependent censoring, although unlikely. We performed a sensitivity analysis using ≥50% ejection fraction defining HFpEF and <50% defining HFrEF and found similar results. We have limited power in our comparison of risk factors for Hispanic American women because of small number of HF events in Hispanic women.
Conclusion
This study demonstrated the higher incidence rate for newonset hospitalized HFpEF compared with HFrEF. Differential risk factors for new-onset HFpEF included obesity, number of comorbidities, anemia, and atrial fibrillation, whereas cigarette smoking, diabetes mellitus, hypertension, and CHD were risk factors for both types of HF. Obesity was found to be a more potent risk factor for African American women compared with white women for HFpEF and showed a trend in Hispanic women. Because HFpEF is growing in incidence and prevalence as the population ages, and limited effective treatment for HFpEF are presently available, preventive strategies focusing on hypertension and obesity given their high PAR% seem most promising.
